Papers › leukemia › 6397669

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

Cancer discovery · 01-3-2019 · 6397669 on PMC →

565 citations FWCI 34.66 Acute Myeloid Leukemia Research Trend

Citation data as of 2026-04-12 (OpenAlex).

Extracted findings

This paper hasn't been extracted into the knowledge graph yet. We're working through the corpus — 6397669 is in the queue.

In the meantime: Browse leukemia papers → · Ask about this topic → · Explore the graph →